Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Jerry A. Krishan, MD, PhD LAB

Breathe Chicago Center

The Breathe Chicago Center (BCC) is a clinical research program within the division of Pulmonary, Critical Care, Sleep and Allergy at the University of Illinois Chicago.  Our lab has expertise in late-stage translational research (“healthcare delivery science”), including the methods of stakeholder engagement, systematic reviews, guideline development, clinical effectiveness studies (observational studies and pragmatic clinical trials), implementation science, and the integration of human-centered design in healthcare. We conduct multi-center cohort studies and clinical trials along the discovery to delivery science spectrum to identify, evaluate, and implement new healthcare strategies for patients with asthma, chronic obstructive pulmonary disease (COPD), COVID-19, and post-acute sequelae of SARS-CoV-2.More information about us and the work we do is available at:  and

Selected Key Publications Heading link

  1. Clinical efficacy trial in outpatient acute COVID-19. Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ, Handberg E, Haight DO, Wilson JW, Majercik S, Fu Z, Zhong Y, Venugopal V, Beach S, Wisniewski S, Ridker PM; ACTIV-4B Investigators. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1703-1712. PMID: 34633405
  2. COPD guidelines. Wedzicha JA ERS Co-Chair, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA ATS Co-Chair. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017 Mar 15;49(3):1600791. PMID: 33185464
  3. Home oxygen guidelines. Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, Carlin B, Drummond MB, Ekström M, Garvey C, Graney BA, Jackson B, Kallstrom T, Knight SL, Lindell K, Prieto-Centurion V, Renzoni EA, Ryerson CJ, Schneidman A, Swigris J, Upson D, Holland AE. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-e141. PMID: 33185464
  4. Asthma guidelines. Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF Jr, Pace W, Schatz M. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. JAMA. 2020 Dec 8;324(22):2301-2317. PMID: 33270095
  5. Pragmatic clinical trial in COPD. LaBedz SL, Prieto-Centurion V, Mutso A, Basu S, Bracken NE, Calhoun EA, DiDomenico RJ, Joo M, Pickard AS, Pittendrigh B, Williams MV, Illendula S, Krishnan JA. Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PArTNER study. J Gen Intern Med. 2022 Mar 8. doi: 10.1007/s11606-022-07461-0. Online ahead of print. PMID: 35260961
  6. Systematic reviews. Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, Prasad B, Bracken N, Didomenico R, Godwin PO, Jaffe HA, Kalhan R, Pickard AS, Pittendrigh BR, Schatz B, Sullivan JL, Thomashow BM, Williams MV, Krishnan JA. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review. Ann Am Thorac Soc. 2014 Mar;11(3):417-24. PMID: 24423379

Research Heading link

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) pragmatic clinical trial

Funding: Patient Centered Outcomes Research Institute, Identifier: NCT04069312

Brief description:  The objective is to compare the real-world effectiveness of chronic roflumilast versus azithromycin therapy in high-risk patients with COPD, with a primary outcome of hospitalization or death.  Secondary outcomes are patient-reported measures of physical function, problems with sleep, fatigue, anxiety, and ability to perform usual activities, measured using the NIH-PROMIS instruments. Participants will be followed up for a period of 6 months (minimum) to 36 months (maximum).


CONNECTS Trial Participant Registry (RE-CONNECTS)        

Funding: NIH/NHLBI

Brief description:  The objectives of the RE-CONNECTS study are to evaluate whether host-directed anti-thrombo-vasculo-inflammatory interventions for acute COVID-19 influence long term outcomes after SARS-CoV-2 infection; conduct investigations on possible mechanisms by which interventions affect long term outcomes after SARS-CoV-2 infection; and create an engaged community of participants previously enrolled in acute COVID-19 studies that will inform and contribute to the success of future NHLBI programs.



Brief description: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults Retrospective and prospective cohort study with nested case-control studies to 1) characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection; 2) characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history, and distinct phenotypes identified as sequelae of SARS-CoV-2 infection; 3) define the biological mechanisms underlying pathogenesis of the sequelae of SARS-CoV-2 infection.